Abdel Salam, M., Mohamed, M., Kamel, C., Mahmoud, A. (2017). Study of Vitamin D3 Supplementation on Chronic Kidney Disease (Mineral Bone Disease (CKD – MBD) Parameters in Patients with Chronic Kidney Disease Stage 3). The Egyptian Journal of Hospital Medicine, 69(2), 1941-1949. doi: 10.12816/0040627
Mona Hosny Abdel Salam; Mohamed Mostafa Mohamed; Cherry Reda Kamel; Abdelkhalek Fouad Mahmoud. "Study of Vitamin D3 Supplementation on Chronic Kidney Disease (Mineral Bone Disease (CKD – MBD) Parameters in Patients with Chronic Kidney Disease Stage 3)". The Egyptian Journal of Hospital Medicine, 69, 2, 2017, 1941-1949. doi: 10.12816/0040627
Abdel Salam, M., Mohamed, M., Kamel, C., Mahmoud, A. (2017). 'Study of Vitamin D3 Supplementation on Chronic Kidney Disease (Mineral Bone Disease (CKD – MBD) Parameters in Patients with Chronic Kidney Disease Stage 3)', The Egyptian Journal of Hospital Medicine, 69(2), pp. 1941-1949. doi: 10.12816/0040627
Abdel Salam, M., Mohamed, M., Kamel, C., Mahmoud, A. Study of Vitamin D3 Supplementation on Chronic Kidney Disease (Mineral Bone Disease (CKD – MBD) Parameters in Patients with Chronic Kidney Disease Stage 3). The Egyptian Journal of Hospital Medicine, 2017; 69(2): 1941-1949. doi: 10.12816/0040627
Study of Vitamin D3 Supplementation on Chronic Kidney Disease (Mineral Bone Disease (CKD – MBD) Parameters in Patients with Chronic Kidney Disease Stage 3)
1Internal Medicine Department, Faculty of Medicine, Ain Shams University
2Internal Medicine, Ministry of Health, Cairo , Egyp
Abstract
Background: Bone profile parameters are affected by decreased estimated GFR within chronic kidney disease stage 3. We aimed to investigate if bone profile parameters response to vitamin D3 supplementation , within this stage , became affected by the presence or absence of diabetic state. Materials and methods: 30 patients having chronic kidney disease (stage 3) were enrolled in the study. 19 patients constituted non – diabetic group I and 11 patients constituted diabetic group II . All of them have received vitamin D3 1000 IU daily for 3 months . For all patients the following measurements were performed before and after vitamin D3 use :CBC , ESR1 & ESR2 , blood urea , serum creatinine , estimated GFR , complete urine analysis , serum Na , protein / creatinine ratio , serum calcium , serum phosphorus , calcium – phosphorus product , serum albumin , serum alkaline phosphatase , and intact serum parathyroid hormone. Results: Serum calcium levels have increased, while intact parathyroid hormone has decreased within both groups , with a more obvious response within the diabetic group . Serum alkaline phosphatase , serum phosphorus , and calcium – phosphorus product did not show any significant change, they were within their level after vitamin d3 use .ESR 1 and ESR 2 levels were higher from the start of the study within the diabetic group. Their mean level values have significantly decreased in a highly significant way within this group . Kidney function parameters and proteinuria have been deteriorated within the two groups , being worse within the diabetic group . Conclusion: Vitamin D3 use within stage 3 chronic renal disease patients is effective for patients support against bone mineral disturbances occurring within this disease .
View on SCiNiTO
Top